Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Posted on 30 Apr 2024
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces the efficacy of treatments for various infectious diseases, jeopardizing significant medical advancements and substantially inflating healthcare costs. The World Health Organization (WHO) stresses the importance of preventing infections, ensuring universal access to quality diagnostic and treatment options, and fostering innovation in surveillance and research as critical strategies to combat AMR in human health. In a significant stride towards preventing AMR, a groundbreaking medical device has been developed to accurately differentiate between viral and bacterial infections, thereby assisting doctors in administering precise and effective treatment.
Developed by Smart Blood Analytics Swiss (Zürich, Switzerland), the VIRUS vs. BACTERIA Clinical Decision Support Software utilizes just 17 routine blood parameters, biological sex, and age to effectively distinguish between viral and bacterial infections. With routine blood testing widely available globally, VIRUS vs. BACTERIA significantly enhances the ability of physicians to differentiate between viral and bacterial infections and supports the rational use of antibiotics, particularly in scenarios where traditional blood markers have limited diagnostic value.
The VIRUS vs. BACTERIA Clinical Decision Support Software has been awarded EU-MDR (European Medical Device Regulation) certification. As the healthcare sector continues to confront challenges that demand innovative responses, VIRUS vs. BACTERIA represents a promising solution. With its global availability, user-friendly interface, and robust capabilities, this advanced tool is well-positioned to empower healthcare professionals in their ongoing fight against AMR.
"This achievement shows our commitment to advancing healthcare through innovation,” said Dr. Marko Notar, CEO of Smart Blood Analytics Swiss. “By providing clinicians with a precise tool to differentiate between viral and bacterial infections, we aim to empower doctors with more information and help them in their decision of antibiotic prescriptions. This contributes to more effective healthcare practices."
Related Links:
Smart Blood Analytics Swiss
